Form 4: Janux Therapeutics Executive Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Andrew Hollman Meyer, Chief Business Officer of Janux Therapeutics, sold shares of common stock on February 3, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On February 3, 2025, Andrew Hollman Meyer, the Chief Business Officer of Janux Therapeutics, executed transactions involving the company's common stock.
- Meyer exercised options to acquire 3,334 shares at a price of $4.21.
- He also sold a total of 3,334 shares in multiple transactions at weighted average prices of $42.0756, $42.7703 and $43.6.
- These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 30, 2024.
- Following these transactions, Meyer directly owns 82,139 shares of Janux Therapeutics common stock and 97,333 stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects routine transactions under a pre-existing trading plan. There is no indication of positive or negative implications for the company.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The stock sale by an executive could have a minor negative impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | Date of adoption of Rule 10b5-1 trading plan |
| 2025-02-03 | Date of stock option exercise and sales |
| 2025-02-05 | Date of signature on the Form 4 filing |
| 2031-03-09 | Expiration date of stock options |
Keywords
Janux Therapeutics, Andrew Hollman Meyer, stock sale, Form 4, Rule 10b5-1, insider trading, JANX, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.